Thursday, October 3, 2013 | 09:00 — 16:30
The Catalent Institute and world-class expert instructors from University of Bath, 3M, BASF, Catalent Pharma Solutions and Formac Pharmaceuticals partnered to deliver the, “Overcoming Bioavailability Challenges,” an interactive educational event focused on drug development challenges facing R&D teams today at the Royal Society of Chemistry in London.
Ms. Robinson has over 25 years of experience in pharmaceutical strategy, development and program management. Her expertise includes bringing business and technical leaders together to create shared vision and achieve mutual objectives. Prior to her current role, Ms. Robinson was Executive Director of Global Accounts responsible for Catalent’s largest strategic customers and was named Executive Director of the Catalent Applied Drug Delivery Institute as of February 2013. Ms. Robinson holds a Bachelor’s degree in Psychobiology as well as a Certificate in Aging Studies from The University of Virginia.
Dr. Robert Price is a professor of Pharmaceutics at the Department of Pharmacy and Pharmacology, University of Bath, where he leads the pharmaceutical surface science research group. Prof. Price’s research has been focused on developing an understanding of how the chemistry, manufacturing and controls of materials and processing conditions determine the structure of formulations and influence product functionality. His research focus has mainly been on orally inhaled drug products and research areas include crystallization, particle processing and characterization and formulation processing. With a strong background in pharmaceutical surface science, Price has developed an array of technologies and techniques to measure the physical, chemical and interfacial properties of excipient and active pharmaceutical ingredients. His research group has published over 70 scientific papers on the properties of crystals, particles and powders for orally inhaled drug products.
Andreas is supporting BASF’s activities in hot-melt extrusion technology. Andreas’ expertise is mainly on Solubility Enhancement, controlled release systems, low temperature melt extrusion prohnology from University of Applied Sciences Magdeburg in 1999. Andreas Gryczke has co-authored 8 research papers, book chapter, 8 patents and numerous conference abstracts. He is invited reviewer for the European Journal of Pharmaceutics and Biopharmaceutics. Andreas is member of International Association for Pharmaceutical Technology and he is member of the American Association of Pharmaceutical Scientists.
Dr. Julien Meissonnier has 15 years of experience in pharmaceutical development and leads Catalent’s European R&D Platform for the development of lipid-based drug delivery solutions. He provides technical and scientific leadership for the development of poorly soluble drugs that lead to approvable regulatory dossiers. Mr. Meissonnier received his Engineer Degree in Physico-Chemistry from the ISMRa in Caen, France. He is an expert in his field and currently sits on the Board of Directors with the Alsace BioValley life sciences and healthcare cluster based in France. As a board member, he supports Alsace BioValley in its efforts to continue driving growth in the life sciences by identifying and coordinating ambitious projects that will create employment opportunities in the region.
Dr. MacGregor, a pharmacist with a PhD in topical cytotoxic drug delivery, from DeMontfort University, Leicester, has nearly 20 years of experience in the pharmaceutical industry. She has had functional and leadership roles in a number of pharmaceutical companies and has technical expertise in development of oral solid, topical, and inhalation dosage forms.
Dr. Michiel Van Speybroeck, Ph.D. is currently R&D Director of Formac Pharmaceuticals, where he oversees the company’s internal and external R&D programs. During his graduate studies at the University of Leuven, Michiel studied the utility of mesoporous silica materials as dissolution-enhancing excipients. His expertise in this field is highly relevant to the activities of Formac.
Akan Oton is responsible for managing Catalent’s technology roadmap, related licensing activities and leading technology related due diligence activities in support of M&A. In addition, he serves as a Director of Catalent’s Applied Drug Delivery Institute.
